Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1970 1
1971 2
1972 6
1973 17
1974 14
1975 23
1976 21
1977 26
1978 10
1979 15
1980 19
1981 20
1982 9
1983 18
1984 12
1985 8
1986 13
1987 14
1988 12
1989 9
1990 18
1991 20
1992 3
1993 12
1994 6
1995 11
1996 5
1997 6
1998 12
1999 7
2000 14
2001 8
2002 14
2003 28
2004 35
2005 38
2006 48
2007 63
2008 47
2009 60
2010 81
2011 102
2012 131
2013 127
2014 120
2015 155
2016 199
2017 265
2018 355
2019 523
2020 808
2021 584
Text availability
Article attribute
Article type
Publication date

Search Results

3,712 results
Results by year
Filters applied: . Clear all
Page 1
The potential of cannabidiol in the COVID-19 pandemic.
Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, Sarnelli G. Esposito G, et al. Br J Pharmacol. 2020 Nov;177(21):4967-4970. doi: 10.1111/bph.15157. Epub 2020 Jul 16. Br J Pharmacol. 2020. PMID: 32519753 Free PMC article.
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the …
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the h …
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Campos AC, et al. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Pharmacol Res. 2016. PMID: 26845349 Review.
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. ...
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. ...
Antioxidative and Anti-Inflammatory Properties of Cannabidiol.
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Atalay S, et al. Antioxidants (Basel). 2019 Dec 25;9(1):21. doi: 10.3390/antiox9010021. Antioxidants (Basel). 2019. PMID: 31881765 Free PMC article. Review.
Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of Cannabis sativa L. ...
Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of Cannabis sativa L. ...
Cannabidiol (CBD) as a Promising Anti-Cancer Drug.
Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D. Seltzer ES, et al. Cancers (Basel). 2020 Oct 30;12(11):3203. doi: 10.3390/cancers12113203. Cancers (Basel). 2020. PMID: 33143283 Free PMC article. Review.
Recently, cannabinoids, such as cannabidiol (CBD) and delta(9) -tetrahydrocannabinol (THC), have been the subject of intensive research and heavy scrutiny. ...
Recently, cannabinoids, such as cannabidiol (CBD) and delta(9) -tetrahydrocannabinol (THC), have been the subject of intensive resear …
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabidiol group, and 76 to the placebo group. ...The median percent reduction from baseline in drop-seizure frequency during the treatment per …
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabid
Cannabidiol: State of the art and new challenges for therapeutic applications.
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Pisanti S, et al. Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Pharmacol Ther. 2017. PMID: 28232276 Review.
Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. delta(9)-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both co …
Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. …
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experiment …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subj …
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Pediatr Neurol. 2019. PMID: 31053391 Review.
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have a novel anticonvulsant effect. ...Additionally, the FDA-approved pharmaceutical-grade cannabidiol oil is expensive, and insurance co …
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have …
Cannabis and epilepsy.
Thomas RH, Cunningham MO. Thomas RH, et al. Pract Neurol. 2018 Dec;18(6):465-471. doi: 10.1136/practneurol-2018-002058. Epub 2018 Oct 18. Pract Neurol. 2018. PMID: 30337476 Review.
The general population appears to be showing a fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs. It is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread le …
The general population appears to be showing a fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs. It …
3,712 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page